Wren Laboratories, a leader in liquid biopsy diagnostics, confirms the official discontinuation of the original NETest 1.0, which has been replaced by the cutting-edge NETest 2.0. This next-generation test marks a significant advancement in precision medicine for neuroendocrine tumor (NET) diagnostics.

NETest 2.0 is an AI-enhanced, non-invasive liquid biopsy test that leverages a refined 51-gene mRNA expression algorithm to offer unmatched diagnostic and prognostic accuracy:

●  >95% sensitivity for detecting NETs

●  >90% accuracy in identifying progressive disease

●  PPQ Score – Predicts patient response to PRRT (98% PPV, 93% NPV)

●  Validated in patient cohorts across the U.S., Europe, Latin America, Africa, and Asia

“NETest 2.0 represents a major leap forward in patient surveillance and therapeutic decision-making for individuals with NETs,” said Dr. Abdel Halim, PharmD, PhD, CEO/CSO of Wren Laboratories. “By integrating advanced machine learning with extensive global validation, we’re setting a new standard for non-invasive tumor monitoring.”

“Clinicians need a reliable, data-driven tool to make informed treatment decisions,” added Dr. Mark Kidd, Laboratory Director at Wren Laboratories. “With NETest 2.0, we’ve significantly enhanced diagnostic precision, allowing for improved patient surveillance and better treatment outcomes.”

“NET patients, specifically being treated with radiopharmaceutical therapies and under active surveillance may profit from state-of-the-art biomarkers like NETest2.0,” shared by nuclear medicine expert and associate professor of radiology for Mallinckrodt Institute of Radiology at Washington University School of Medicine of St. Louis, Dr. Vikas Prasad, MD, PhD. “Integration of the 51-gene mRNA expression-based biomarker with imaging biomarker has the potential to further improve NET patients care.”